Neffy Momentum and International Filings Create a Tactical Long on SPRY
ARS Pharmaceuticals (SPRY) is printing accelerating neffy sales and expanding regulatory filings through licensing partners in multiple large markets. With revenue jumping to $32.5M in Q3 2025 and prescription volumes accelerating, the setup favors a tactical long over the next 45 trading days if price holds support and sentiment stabilizes. The tr…